Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma

[1] Holohan C(2013)Cancer drug resistance: an evolving paradigm Nat Rev Cancer 13 714-26

[2] Van Schaeybroeck S(2012)The evolving contribution of hematopoietic progenitor cells to lymphomagenesis Blood 120 2553-61

[3] Longley DB(2011)Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer Mol Pharm 8 2069-79

[4] Johnston PG(2009)Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea Ann Hematol 88 1099-106

[5] Weigert O(2010)Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma Blood 116 2531-42

[6] Weinstock DM(2012)Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance Drug Resist Updat 15 21-38

[7] Mumenthaler SM(2014)An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia Nat Genet 46 364-70

[8] Foo J(2009)Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance Blood 113 4885-93

[9] Leder K(2013)Decitabine represses translocated MYC oncogene in Burkitt lymphoma J Pathol 229 775-83

[10] Choi NC(2012)Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines Exp Hematol 40 800-10

[1] Holohan C(2013)Cancer drug resistance: an evolving paradigm Nat Rev Cancer 13 714-26

[2] Van Schaeybroeck S(2012)The evolving contribution of hematopoietic progenitor cells to lymphomagenesis Blood 120 2553-61

[3] Longley DB(2011)Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer Mol Pharm 8 2069-79

[4] Johnston PG(2009)Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea Ann Hematol 88 1099-106

[5] Weigert O(2010)Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma Blood 116 2531-42

[6] Weinstock DM(2012)Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance Drug Resist Updat 15 21-38

[7] Mumenthaler SM(2014)An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia Nat Genet 46 364-70

[8] Foo J(2009)Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance Blood 113 4885-93

[9] Leder K(2013)Decitabine represses translocated MYC oncogene in Burkitt lymphoma J Pathol 229 775-83

[10] Choi NC(2012)Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines Exp Hematol 40 800-10